Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhibituo is a proprietary Chinese medicine containing red yeast rice (Monascus purpureus) as a main active ingredient, often formulated with other herbs. The primary therapeutic effect is lipid-lowering, working mainly through inhibition of HMG-CoA reductase, which reduces cholesterol synthesis in the liver. The main bioactive component, lovastatin (monacolin K), is identical to the statin drug lovastatin. Zhibituo is used to manage hyperlipidemia and cardiovascular risk, with studies supporting its effect in improving lipid profiles, specifically lowering LDL-C, total cholesterol, and triglycerides while increasing HDL-C. It is typically administered orally as capsules or dropping pills[1][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhibituo.